BRISBANE, Calif., July 21, 2026 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clini

Amova Asset Management Americas Inc. cut its position in shares of Nurix Therapeutics, Inc. (NASDAQ:

Roche wins FDA Priority Review for Gazyva in primary membranous nephropathy, with a decision due by

Mizuho analyst Joseph Catanzaro maintains Nurix Therapeutics (NASDAQ:NRIX) with a Outperform and

Truist Securities analyst Gregory Renza maintains Nurix Therapeutics (NASDAQ:NRIX) with a Buy and

RBC Capital analyst Brian Abrahams maintains Nurix Therapeutics (NASDAQ:NRIX) with a Outperform a

Stifel analyst Stephen Willey maintains Nurix Therapeutics (NASDAQ:NRIX) with a Buy and raises th

BTIG analyst Jeet Mukherjee reiterates Nurix Therapeutics (NASDAQ:NRIX) with a Buy and maintains

HC Wainwright & Co. analyst Robert Burns maintains Nurix Therapeutics (NASDAQ:NRIX) with a Bu

Nurix Therapeutics, Inc. (NRIX) came out with a quarterly loss of $0.81 per share versus the Zacks C

Nurix Therapeutics (NASDAQ:NRIX) reported quarterly losses of $(0.81) per share which missed the ana

Entered into global collaboration with Roche for bexobrutideg, with potential total payments of up t

Nurix Therapeutics (NRIX) doesn't possess the right combination of the two key ingredients for a lik

The mean of analysts' price targets for Nurix Therapeutics (NRIX) points to a 29.2% upside in the st

Health care stocks flashing warning to momentum investors. RSI indicator shows overbought for DFTX,

NRIX rallies on its collaboration with Roche for bexobrutideg, featuring a $700 million upfront paym

Nurix Therapeutics (NRIX) saw its shares surge in the last session with trading volume being higher

Gainers Atlantic International (NASDAQ:ATLN) shares increased by 41.0% to $1.1 during Thursday'

Recently, Nurix secured a partnership with Roche, which I believe has substantially derisked the sto

High objective response rate of 92.9% in second line patients who have progressed on a BTK inhibitor

Nurix Therapeutics, Inc. remains a Strong Buy as bexobrutideg advances in pivotal r/r CLL trials and

Wall Street analysts change outlook on top names. B of A cuts CPB, UBS cuts AJG PT, B of A boosts OR

Nurix Therapeutics (NRIX) was a big mover last session on higher-than-average trading volume. The la

Nurix Therapeutics, Inc. (NRIX) Discusses Strategic Collaboration for Development and Commercializat

Roche Holding AG (RHHBY) has agreed to pay Nurix Therapeutics (NRIX) as much as $2.3 billion for rig

Roche collaborates with Nurix on bexobrutideg, a BTK degrader for blood cancers, while expanding pot

Nurix Therapeutics strikes an agreement with Roche to commercialize its lead asset, bexobrutideg.

Nurix Therapeutics stock bounded of its 50-day line Monday after inking a deal with Roche for its BT

Nurix Therapeutics Inc (NASDAQ:NRIX) stock is up 15.7% to trade at $16.94, after the biotech company

Nurix Therapeutics, Inc. (NASDAQ:NRIX) stock is up during Monday's premarket session as the company

href=https://www.benzinga.com/quote/RMSG target=_blank>(NASDAQ: RMSG) lost 67.6% to $0.69 in

  On Wednesday, 311 stocks hit new 52-week lows.

  On Tuesday, 647 companies set new 52-week lows.

  During Thursday's session, 406 companies made new 52-week lows.

  On Wednesday, 807 companies reached new 52-week lows.

  During Thursday, 849 stocks hit new 52-week lows.

    Tuesday's session saw 729 companies set new 52-week lows.

    On Thursday, 147 companies achieved new lows for the year.